$SHPH

HRT FINANCIAL LP sold $32K of SHPH

HRT FINANCIAL LP sold 9,022 shares of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) at $3.51 on 2026-07-06.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 7, 2026, 8:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SHPH
Neutral
low confidence
Mentioned
$SHPH
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SHPHNeutralLow
01

Why it matters

The newest concrete fact is the reported sale of 9,022 shares at $3.51 on 2026-07-06, with holdings after the transaction of 81,385 shares; no company performance or guidance changes are disclosed.

02

Market read

Traders may monitor for continued insider selling, but the filing alone does not provide a new fundamental catalyst.

03

What to watch

The article lacks context on total holdings over time, whether other insiders sold, and whether the sale was part of broader planned diversification.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-07 after-hours; reflects sale executed 2026-07-06.

Background

This is an SEC Form 4 insider transaction filed by HRT Financial LP, identified as a 10% owner of Shuttle Pharmaceuticals Holdings, Inc.

Company-level read

Ticker impact

$SHPHNeutralLow confidence
Context

HRT Financial LP, a 10% owner of Shuttle Pharmaceuticals, sold 9,022 shares in an open-market transaction at $3.51 on 2026-07-06.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless follow-on filings show sustained selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a small-to-moderate dollar value and no 10b5-1 plan stated; however, insider sales are often non-informational and the article provides no additional company-specific catalyst.

Market effects

No clear sector read-through; this is a single-company insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is open-market and not clearly linked to a 10b5-1 plan, it could be interpreted as liquidity/portfolio management rather than bearish information.

Key entities

  • Shuttle Pharmaceuticals Holdings, Inc.

    Subject of the Form 4 insider transaction; 10% owner HRT Financial LP sold shares.

  • HRT Financial LP

    10% owner who executed the open-market sale reported in the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles